Correction to: Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effect (Cellular & Molecular Immunology, (2010), 7, 4, (296-305), 10.1038/cmi.2010.15);Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effect

Cellular and Molecular Immunology

Volumn 7, Issue 4, 2010, Pages 296-305

  Hu, Guili ^a   Liu, Yang ^a   Li, Hong ^b   Zhao, Dekuang ^a   Yang, Liuqing ^a   Shen, Jiangen ^a   Hong, Xuejun ^a   Cao, Xuetao ^a,c   Wang, Qingqing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

adenovirus; B lymphoma; gene transfer; LIGHT TNFSF14

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CXCL9 CHEMOKINE; FAS ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HERPESVIRUS ENTRY MEDIATOR LIGAND; INTERCELLULAR ADHESION MOLECULE 1; SECONDARY LYMPHOID TISSUE CHEMOKINE; CHEMOKINE; TNFSF14 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER INFILTRATION; CANCER TISSUE; CELL STIMULATION; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; GENE THERAPY; GENETICS; IMMUNITY; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL; SPLEEN; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR VOLUME;

ADENOVIRIDAE; MURINAE; MUS;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CHEMOKINES; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNITY; IMMUNIZATION; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 77957285966     PISSN: 16727681     EISSN: 20420226     Source Type: Journal    
DOI: 10.1038/s41423-019-0356-4     Document Type: Erratum

References (36)

1. LaCasce AS, Kho ME, Friedberg JW, Niland JC, Abel GA, Rodriguez MA et al. Comparison of referring and final pathology for patients with non-Hodgkińs lymphoma in the National Comprehensive Cancer Network. J Clin Oncol 2008; 26: 5107-5112.
2. Seshadri T, Stakiw J, Pintilie M, Keating A, Crump M, Kuruvilla J. Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy. Hematology 2008; 13: 261-266.
3. Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkińs lymphoma: a 20-year followup analysis of SWOG 8516 - the Southwest Oncology Group. J Clin Oncol 2009; 27: 114-119.
4. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkińs lymphoma. N Engl J Med 2008; 359: 613-626.
5. Mezianeel K, Bhattacharyya T, Armstrong AC, Qian C, Hawkins RE, Stern PL, et al. Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer 2004; 111: 910-920. (Pubitemid 39096240)
6. Ulaner GA, Colletti PM, Conti PS. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy - initial experience. Radiology 2008; 246: 895-902.
7. Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 2004; 10: 2530-2537. (Pubitemid 38445715)
8. Hurwitz AA, Kwon ED, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol 2000; 12: 589-596.
9. Celli S, Garcia Z, Beuneu H, Bousso P. Decoding the dynamics of T cell-dendritic cell interactions in vivo. Immunol Rev 2008; 221: 182-187. (Pubitemid 351230115)
10. Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995; 92: 8200-8204.
11. Vyth-Dreese FA, Dellemijn TA, van Oostveen JW, Feltkamp CA, Hekman A. Functional expression of adhesion receptors and costimulatory molecules by fresh and immortalized B-cell non-Hodgkińs lymphoma cells. Blood 1995; 85: 2802-2812.
12. Stopeck AT, Gessner A, Miller TP, Hersh EM, Johnson CS, Cui H et al. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res 2000; 6: 3904-3909.
13. Briones J, Timmerman J, Levy R. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res 2002; 62: 3195-3199. (Pubitemid 34602413)
14. Costello RT, Mallet F, Barbarat B, Schiano de Colella JM, Sainty D, Sweet RW et al. Stimulation of non-Hodgkińs lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity. Leukemia 2003; 17: 2500-2507. (Pubitemid 38072590)
15. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998; 8: 21-30. (Pubitemid 28097820)
16. Zhai Y, Guo R, Hsu TL, Yu GL, Ni J, Kwon BS et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 1998; 102: 1142-1151. (Pubitemid 28436274)
17. Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, Chen SF et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000; 164: 4105-4110. (Pubitemid 30215066)
18. Tamada K, Shimozaki K, Chapoval AI, Zhu G, Sica G, Flies D et al. Modulation of Tcell- mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 2000; 6: 283-289. (Pubitemid 30148620)
19. Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004; 5: 141-149. (Pubitemid 38208355)
20. Wang Q, Yu H, Ju DW, He L, Pan JP, Xia DJ et al. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma. Gene Ther 2001; 8: 542-550. (Pubitemid 32409529)
21. Zoll B, Lefterova P, Csipai M, Finke S, Trojaneck B, Ebert O et al. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother 1998; 47: 221-226. (Pubitemid 29009677)
22. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008; 68: 3915-3923.
23. Fuertes MB, Girart MV, Molinero LL, Domaica CI, Rossi LE, Barrio MM et al. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol 2008; 180: 4606-4614.
24. Lu B, Finn OJ. T-cell death and cancer immune tolerance. Cell Death Differ 2008; 15: 70-79. (Pubitemid 350286174)
25. Ye Q, Fraser CC, Gao W, Wang L, Busfield SJ, Wang C et al. Modulation of LIGHTHVEM costimulation prolongs cardiac allograft survival. J Exp Med 2002; 195: 795-800. (Pubitemid 34259724)
26. Scheu S, Alferink J, Potzel T, Barchet W, Kalinke U, Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med 2002; 195: 1613-1624. (Pubitemid 34666074)
27. Mortarini R, Scarito A, Nonaka D, Zanon M, Bersani I, Montaldi E et al. Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles. Cancer Res 2005; 65: 3428-3436. (Pubitemid 40524629)
28. Yu P, Lee Y, Wang Y, Liu X, Auh S, Gajewski TF et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 2007; 179: 1960-1968.
29. Diamond MS, Staunton DE, Marlin SD, Springer TA. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell 1991; 65: 961-971. (Pubitemid 121001684)
30. Lebedeva T, Dustin ML, Sykulev Y. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol 2005; 17: 251-258. (Pubitemid 40692659)
31. Dennig D, Lacerda J, Yan Y, Gasparetto C, ÓReilly RJ. ICAM-1 (CD54) expression onB lymphocytes is associated with their costimulatory function and can be increased by coactivation with IL-1 and IL-7. Cell Immunol 1994; 156: 414-423.
32. Hisada M, Yoshimoto T, Kamiya S, Magami Y, Miyaji H, Yoneto T et al. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Ther 2004; 11: 280-288. (Pubitemid 41184347)
33. Fan Z, Yu P, Wang Y, Wang Y, Fu ML, LiuW et al. NK-cell activation by LIGHT triggers tumor-specific CD81 T-cell immunity to reject established tumors. Blood 2006; 107: 1342-1351. (Pubitemid 43242367)
34. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000; 18: 593-620. (Pubitemid 30365392)
35. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195-3204. (Pubitemid 34256349)
36. Zhang R, Tian L, Chen LJ, Xiao F, Hou JM, Zhao X et al. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther 2006; 13: 1263-1271. (Pubitemid 44264080)